Microneedle array: applications, recent advances, and clinical pertinence in transdermal drug delivery
Most users begin noticing appetite changes in the first few weeks and measurable weight loss by weeks 48
Semaglutide is available as both an injectable and an oral tablet
Key Safety Checkpoints Before Starting GLP-1 Therapy Before initiating any GLP-1 medication, Crohn's patients must confirm disease remission or minimal inflammation through recent lab work (CRP, fecal calprotectin) and imaging if available
Strategies to mitigate muscle loss include: Prioritizing protein at each meal before other macronutrients Incorporating resistance training at least 23 times weekly Monitoring body composition, not just scale weight Working with your healthcare provider if side effects prevent adequate nutritionnever adjust medication doses on your own Contact your healthcare provider immediately if you experience: Severe or persistent nausea, vomiting, or abdominal pain Signs of dehydration (extreme thirst, dizziness, dark urine) Low blood sugar symptoms (if taking insulin or sulfonylureas) Inability to eat or drink for more than 24 hours Selecting appropriate protein sources is essential for patients on GLP-1 therapy, particularly given the reduced appetite and early satiety these medications produce
Bioresour Technol 120:225232
